SteriMax Expands Reach with Andone Pharmaceuticals Acquisition
Oakville-based SteriMax Inc. has acquired Andone Pharmaceuticals, a strategic move that pushes the private Canadian drugmaker into the medical device and veterinary sectors. The deal integrates Andone’s diversified commercial verticals with SteriMax’s established portfolio of sterile injectables, signaling a shift toward broader healthcare market coverage.
Andone founder Jay Barat will join the SteriMax leadership team to oversee the newly acquired veterinary and medical device operations. The move is designed to leverage SteriMax’s existing distribution strength while scaling Andone’s practical, efficiency-focused solutions across Canada’s hospital, homecare, and clinical landscapes.
Samir Acharya, President and CEO of SteriMax, noted that the acquisition accelerates the company’s push into adjacent markets where long-term growth potential remains high. For SteriMax, which currently supplies approximately 40 million doses annually, the integration provides a platform to expand its customer relationships beyond the standard injectable market. Financial advisory services for the transaction were provided by Bourne Partners for SteriMax and Bloom Burton & Co. for Andone.
Comments (0)
No comments yet. Be the first!